Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE) (ENSEMBLE)

5. november 2026 opdateret af: Travere Therapeutics, Inc.

Et åbent, fase 3 langsigtet forlængelsesstudie (LTE) for at vurdere sikkerheden, tolerabiliteten og effektiviteten af ​​behandling med pegtibatinase hos deltagere med klassisk homocystinuri (HCU) på grund af cystathionin betasyntasemangel (ENSEMBLE)

The goal of this long-term extension (LTE) study is to evaluate the safety and efficacy of pegtibatinase in patients with classical homocystinuria (HCU). Patients who are active in the Phase 1/2 COMPOSE study or those who complete the 24 weeks of blinded treatment in the Phase 3 HARMONY are eligible to participate.

Participants will be in this clinical study for a minimum of 108 weeks including:

a treatment period of up to 104 weeks a 4-week safety follow-up period

Studieoversigt

Status

Tilmelding efter invitation

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Overall Design:

This is a global, multicenter, single-arm, open-label study. Participants who meet all eligibility criteria may transition from other pegtibatinase studies and enroll into this LTE study for long-term safety, efficacy, and clinical assessments of pegtibatinase treatment.

All participants will follow a protocol of self-administration of pegtibatinase unless exempted. During the study, pegtibatinase pharmacokinetic assessments will be conducted. An optional protein tolerance modification (PTM) sub-study will also be conducted for eligible participants.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Adelaide, Australien
        • Royal Adelaide Hospital
      • Parkville, Australien
        • Royal Children's Hospital Melbourne
      • Westmead, Australien
        • Westmead Hospital
      • Brussels, Belgien
        • Cliniques Universitaires Saint-Luc
      • Edegem, Belgien
        • Universitair Ziekenhuis Antwerpen (UZA)
      • Birmingham, Det Forenede Kongerige
        • Birmingham Women's and Children's NHS Foundation Trust
      • Birmingham, Det Forenede Kongerige
        • University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital Birmingham
      • London, Det Forenede Kongerige
        • University College London Hospitals NHS Foundation Trust - National Hospital for Neurology and Neurosurgery
      • Salford, Det Forenede Kongerige
        • Salford Royal NHS Foundation Trust - Salford Royal Hospital
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85006
        • Phoenix Children's Hospital
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06519
        • Yale University School of Medicine
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Emory University
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • Maine
      • Portland, Maine, Forenede Stater, 04012
        • Maine Health Pediatric Specialty Care
    • Maryland
      • Chevy Chase, Maryland, Forenede Stater, 20815
        • Uncommon Cures
    • New York
      • New York, New York, Forenede Stater, 10029
        • Icahn School of Medicine at Mount Sinai
    • North Carolina
      • Morrisville, North Carolina, Forenede Stater, 27560
        • Science 37 - Virtual Site
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Oregon Health and Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • The Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Forenede Stater, 15224
        • University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh
    • Texas
      • Dallas, Texas, Forenede Stater, 75390
        • University of Texas Southwestern Medical Center
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84113
        • Utah Health - The University of Utah Primary Children's Hospital
      • Paris, Frankrig
        • Assistance Publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker-Enfants Malades
      • Tours, Frankrig
        • CHRU Hôpitaux de Tours - Hôpital Bretonneau
      • Vandœuvre-lès-Nancy, Frankrig
        • Centre Hospitalier Régional Universitaire de Nancy (CHRU) - Hopitaux de Brabois - Hôpital d'enfants
      • Dublin, Irland
        • Children's Health Ireland (CHI) at Temple Street
      • Bari, Italien
        • Ospedale Pediatrico Giovanni XXIII
      • Genova, Italien
        • IRCCS Istituto Giannina Gaslini
      • Milan, Italien
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Policlinico di Milano)
      • Monza, Italien
        • Fondazione IRCCS San Gerardo Dei Tintori - Ospedale San Gerardo
      • Padova, Italien
        • Azienda Ospedaliera di Padova
      • Krakow, Polen
        • SP ZOZ Szpital Uniwersytecki w Krakowie
      • Warsaw, Polen
        • Instytut Matki i Dziecka
      • Warsaw, Polen
        • Instytut Pomnik-Centrum Zdrowia Dziecka
      • Coimbra, Portugal
        • Unidade Local de Saúde de Coimbra, EPE - Hospitais da Universidade de Coimbra
      • Lisbon, Portugal
        • Unidade Local de Saúde de Santa Maria, EPE - Hospital de Santa Maria
      • Porto, Portugal
        • Unidade Local de Saúde de São João, EPE - Hospital São João
      • Doha, Qatar
        • Hamad General Hospital
      • Doha, Qatar
        • Sidra Hospital
      • Riyadh, Saudi Arabien
        • King Abdullah International Medical Research Center
      • Riyadh, Saudi Arabien
        • King Faisal Specialist Hospital and Research Centre (KFSHRC) - Riyadh
      • Barcelona, Spanien
        • Hospital Sant Joan de Déu
      • Madrid, Spanien
        • Hospital Universitario 12 de Octubre
      • Madrid, Spanien
        • Hospital Universitario Ramón y Cajal
      • Santiago de Compostela, Spanien
        • Complejo Hospitalario Universitario de Santiago (CHUS) - Hospital Clínico Universitario
      • Seville, Spanien
        • Hospital Universitario Virgen del Rocío
      • Ankara, Tyrkiet (Türkiye)
        • Gazi University Hospital
      • Bornova, Tyrkiet (Türkiye)
        • Ege Üniversitesi Hastanesi Bornova
      • Istanbul, Tyrkiet (Türkiye)
        • Istanbul University Cerrahpasa Hospital
      • Hamburg, Tyskland
        • Universitätsklinikum Hamburg-Eppendorf
      • Leipzig, Tyskland
        • Universitätsklinikum Leipzig
      • Münster, Tyskland
        • Universitätsklinikum Münster

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

5 år til 65 år (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

• Participants active in the COMPOSE study or who completed the 24- week blinded period on study intervention (pegtibatinase or placebo) in the Phase 3 HARMONY study

Exclusion Criteria:

• Participant permanently discontinued from study intervention treatment in a previous pegtibatinase study due to serious AE (SAE) or intolerance

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: pegtibatinase

Pegtibatinase BIW

Andre navne:
  • TVT-058
  • OT-58

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Treatment-emergent AEs
Tidsramme: Week 1 - Week 108

Incidence of treatment-emergent AEs

Week 1 - Week 108
Hypermethioninemia
Tidsramme: Week 1 - Week 108

Incidence of hypermethioninemia

Week 1 - Week 108
Hypomethioninemia
Tidsramme: Week 1 - Week 108

Incidence of hypomethioninemia

Week 1 - Week 108
Dietary Protein Rescue
Tidsramme: Week 1 - Week 108

Proportion of participants requiring dietary protein rescue for participants with hypomethioninemia

Week 1 - Week 108

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Maximum Drug Concentration
Tidsramme: Pharmacokinetic Assessment Period - 4 weeks & 8 weeks

Pegtibatinase pharmacokinetic parameters at steady state - maximum drug concentration [Cmax]

Pharmacokinetic Assessment Period - 4 weeks & 8 weeks
Area under the Curve within the Dosing Interval
Tidsramme: Pharmacokinetic Assessment Period - 4 weeks & 8 weeks

Pegtibatinase pharmacokinetic parameters at steady state within the - area under the curve within the dosing interval [AUC0-tau]

Pharmacokinetic Assessment Period - 4 weeks & 8 weeks
Total Homocysteine (tHcy) Levels
Tidsramme: Week 1 - Week 108

Relative and absolute changes from baseline in tHcy levels

Week 1 - Week 108

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Michael Imperiale, MD, Travere Therapeutics, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. april 2024

Primær færdiggørelse (Anslået)

1. august 2030

Studieafslutning (Anslået)

1. august 2030

Datoer for studieregistrering

Først indsendt

8. maj 2024

Først indsendt, der opfyldte QC-kriterier

21. maj 2024

Først opslået (Faktiske)

29. maj 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Requests for clinical trial data, including language stating its intended use, should be directed to datarequest@travere.com. If approved, the requested information will be provided to the requestor after signing a data access agreement. Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication. Travere reserves the right to decline or recommend modifications to a request if it does not comply with the data sharing policy or if it is determined that the request is made by a biased source.

IPD-delingstidsramme

Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication.

IPD-delingsadgangskriterier

Requires submission and approval of intended use and a data sharing agreement.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner